RxDoctor Payments DataLook up a doctor →

Harrison Starnes, MD

Interventional Cardiology · Little Rock, ARNPI 1285858449

Payments from drug & device makers

$6,118in general payments, 2019–2025

Across 396 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$610
  • Boehringer Ingelheim$591
  • E.r. Squibb & Sons, L.L.C.$461
  • Pfizer$438
  • Amgen$283
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$6,106100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,118 in reported general payments places this provider in the 40th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$326,104
Medicare patients
2,559
Services billed
7,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban745$560,433
EntrestoSacubitril/Valsartan185$160,046
XareltoRivaroxaban90$91,030
JardianceEmpagliflozin127$86,333
Repatha SureclickEvolocumab52$40,173
BrilintaTicagrelor44$28,071
Metoprolol Succinate1,176$12,536
Ranolazine ErRanolazine87$5,616
Praluent PenAlirocumab12$5,517
Atorvastatin Calcium475$4,480
Diltiazem 24hr Er (Cd)Diltiazem Hcl174$3,905
Flecainide Acetate81$3,039
Digoxin150$2,812
Amiodarone Hcl145$2,555
Isosorbide Mononitrate ErIsosorbide Mononitrate189$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$438$560,433745 claims
NovartisEntresto$1,361$160,046185 claims
Johnson & JohnsonXarelto$610$91,03090 claims
Boehringer IngelheimJardiance$591$86,333127 claims
AstraZenecaBrilinta$237$28,07144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →